Actinomycin D is a polypeptide antibiotic first described by Waksman. It is bacteriostatic in nature, especially towards gram negative bacteria. Actinomycin D was the first antibiotic shown to have anti-cancer activity. Produced by several Streptomyces spp.
Actinomycin is a clear, yellow liquid administered intravenously and most commonly used in the treatment of a variety of cancers. Actinomycin D can induce apoptosis in several cell lines such as lung and prostate cancer lines, and human blood lymphocytes.
Used as a radiosensitizer in adjunct to radiotherapies since it can increase the radiosensitivity of tumor cells, by inhibiting repair of sublethal radiation damage and, delay the onset of the compensatory hyperplasia that occurs following irradiation.
In cell biology, actinomycin D is shown to have the ability to inhibit transcription, this occurs by binding DNA at the transcription initiation complex and preventing elongation of RNA chain by RNA polymerase.
Not for human therapeutic use or for medicinal purposes. For research applications only.
|Handling||Warning: Very TOXIC. For research use only. Not for human or drug use. The pharmacological and toxicological properties of this product have not been fully investigated. Use caution when handling. Do not use this compound if you are not fully trained or are unaware of the hazards involved. Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product.|
|UN #'S||UN 3462|